Ikeda, S., Ogura, T., Kato, T., Kenmotsu, H., Iwasawa, T., Misumi, T., . . . Okamoto, H. (2020). Rationale and protocol design for the TORG1835/NEXT-SHIP study: A phase II study of carboplatin, etoposide and nintedanib for unresectable limited/extensive disease small cell lung cancer with idiopathic pulmonary fibrosis. Ther Adv Med Oncol.

Ikeda, Satoshi, Takashi Ogura, Terufumi Kato, Hirotsugu Kenmotsu, Tae Iwasawa, Toshihiro Misumi, Takeharu Yamanaka, και Hiroaki Okamoto. "Rationale and Protocol Design for the TORG1835/NEXT-SHIP Study: A Phase II Study of Carboplatin, Etoposide and Nintedanib for Unresectable Limited/extensive Disease Small Cell Lung Cancer With Idiopathic Pulmonary Fibrosis." Ther Adv Med Oncol 2020.

Ikeda, Satoshi, et al. "Rationale and Protocol Design for the TORG1835/NEXT-SHIP Study: A Phase II Study of Carboplatin, Etoposide and Nintedanib for Unresectable Limited/extensive Disease Small Cell Lung Cancer With Idiopathic Pulmonary Fibrosis." Ther Adv Med Oncol 2020.